Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols
Artificial Organs · 2025
DOI: 10.1111/aor.15010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Hong-Gook Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Ko…. Hauptthemen laut MEDLINE: Pericardium, Bioprosthesis, Calcinosis, Tissue Scaffolds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SNUH Lee Kun-hee Child Cancer & Rare Disease Project, Republic of Korea (Grant Number: 23C0220100).
Abstract (Originalsprache)
Background
Glutaraldehyde (GA) generates cross‐links between cardiovascular xenografts to obtain tissue stability and attenuate antigenicity. However, the long‐term durability of GA‐fixed cardiovascular xenografts treated with previous anticalcification strategies has remained a challenge because tissue phospholipids, free aldehyde groups of GA, and residual antigenicity contribute to calcification. This study aimed to assess the safety, efficacy, and clinical performance of a bovine pericardial scaffold treated with our novel anticalcification protocols (Periborn) in patients with cardiovascular diseases.
Methods
Bovine pericardia were decellularized with 0.25% sodium dodecyl sulfate, 0.5% Triton X‐100, and treated with a space‐filler with polyethylene glycol. These tissues were cross‐linked with 0.5% GA in a 75% ethanol +5% octanol organic solvent and treated with glycine for detoxification to produce Periborn. Between July 2015 and April 2022, 451 Periborn patches were implanted in 352 cases for cardiovascular surgeries.
Results
The mean age at the time of surgery was 22.74 ± 20.09 years (13 days–89.5 years), follow‐up duration was 4.25 ± 2.56 years (17 days–8.6 years), and no patch‐related mortalities were observed. Five patients were reoperated owing to patch‐related complications including decreased mobility, erosion, pseudoaneurysm, and calcification, and the overall probability of freedom from Periborn‐related reoperation was 99.4% ± 0.4% at 1 year, 98.6% ± 0.7% at 5 years, and 95.4% ± 3.2% at 9 years.
Conclusions
This retrospective study demonstrates the safety and efficacy of the tissue‐engineered Periborn bovine pericardial scaffold for the surgical repair of various cardiovascular diseases. The excellent durability and hemodynamic performance of Periborn make our novel anti‐calcification protocol attractive and may require long‐term follow‐up to confirm durability and further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Bucheon, South Korea.
ORCID-Profile: Yong Jin Kim
Förderung
- SNUH Lee Kun-hee Child Cancer & Rare Disease Project, Republic of Korea (Grant Number: 23C0220100)
Zitieren
APA
Lim, H. G., Lee, C. H., Lim, J. H., Kim, E. R., & Kim, Y. J. (2025). Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols. Artificial Organs. https://doi.org/10.1111/aor.15010
Vancouver
Lim HG, Lee CH, Lim JH, Kim ER, Kim YJ. Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols. Artificial Organs. 2025. doi:10.1111/aor.15010
BibTeX
@article{Lim2025,
author = {Lim, Hong-Gook and Lee, Chang Ha and Lim, Jae Hong and Kim, Eung Re and Kim, Yong Jin},
title = {Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.15010}
}
EUVIMED